* Editas Medicine Inc EDIT.OQ reported a quarterly
adjusted loss
of 82 cents per share for the quarter ended in January, lower
than the same quarter last year, when the company reported EPS
of -56 cents. The mean expectation of seventeen analysts for
the quarter was for a loss of 70 cents per share. Wall Street
expected results to range from -84 cents to -46 cents per share.
* Revenue fell 82.2% to $513.00 thousand from a year ago;
analysts
expected $5.08 million.
* Editas Medicine Inc's reported EPS for the quarter was a
loss
of 82 cents.
* The company reported a quarterly loss of $67.61 million.
* Editas Medicine Inc shares had risen by 0.2% this
quarter and
lost 53.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 4.1%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Editas Medicine
Inc is $14.00
This summary was machine generated from LSEG data August 7 at
01:32 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.70 -0.82 Missed
Mar. 31 2024 -0.66 -0.76 Missed
Dec. 31 2023 -0.54 -0.23 Beat
Sep. 30 2023 -0.57 -0.55 Beat